Results 161 to 170 of about 491,626 (323)

Lymphoma Prevalence Patterns in Uganda, 1969-2006

open access: yesMiddle East Journal of Cancer, 2013
Background: Lymphomas are a complex group of malignancies that requireadvanced technology for proper classification. Unfortunately Uganda, as with numerousother Sub-Saharan African countries, lacks these resources.
Adriane Kamulegeya, Louis Muwazi
doaj  

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas

open access: yesAmerican Journal of Hematology, Volume 101, Issue 1, Page 110-128, January 2026.
ABSTRACT The tumor necrosis factor (TNF)‐receptor superfamily 8 receptor CD30 molecule is expressed in all tumor cells of Hodgkin lymphoma and anaplastic large cell lymphoma but is only weakly expressed in a small subset of large lymphoid cells in normal peripheral lymphoid tissues.
Harald Stein, Brunangelo Falini
wiley   +1 more source

Natural Products Targeting Notch Signaling in Cancer: Mechanistic Insights and Food‐Based Chemoprevention Potential

open access: yesFood Frontiers, Volume 7, Issue 1, January 2026.
The Notch signaling pathway plays a dual role in cancer, acting as both a tumor promoter and suppressor depending on cellular context. This review highlights how natural products modulate Notch signaling to inhibit tumor initiation, progression, angiogenesis, and cancer stem cell maintenance.
Rabab Fatima   +15 more
wiley   +1 more source

Supplementary Figure S5 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma

open access: gold, 2023
Xiao-Peng Tian   +53 more
openalex   +1 more source

Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab

open access: yesHematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapies have revolutionized the treatment of hematological malignancies, achieving high response rates in patients with relapsed or refractory disease. Despite these benefits, CAR‐T cell therapies are associated with unique toxicities, including cytokine release syndrome (CRS), immune effector cell ...
Livia Donzelli   +7 more
wiley   +1 more source

Toll‐Like Receptor Polymorphisms Influence Graft‐Versus‐Host Disease and Infection Risk After Single‐Unit Cord Blood Transplantation for Adults

open access: yesEuropean Journal of Haematology, Volume 116, Issue 1, Page 37-45, January 2026.
ABSTRACT Background Toll‐like receptors (TLRs) play a critical role in innate immunity by recognizing pathogen‐associated and damage‐associated molecular patterns. Genetic polymorphisms in TLR genes can modulate immune responses and have been implicated in the outcomes of allogeneic hematopoietic cell transplantation (HCT).
Takaaki Konuma   +10 more
wiley   +1 more source

Chronic Hepatitis B Virus Infection Acquired Under Cytostatic Treatment in Childhood — Clinical, Virological and Immunological Long‐Term Follow‐Up

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 1, January 2026.
ABSTRACT Oncology patients receiving cytostatic therapy used to be at high risk of HBV infection when HBV screening measures were less reliable. Infections acquired under these conditions often persist, like those acquired perinatally or during early infancy.
Thomas Baumgarten   +10 more
wiley   +1 more source

Secondary Thymoma among Adult Treated For Acute Lymphoblastic Lymphoma/Leukemia: Report of a Case and Review of the Literature

open access: diamond, 2018
Mounia Bendari   +9 more
openalex   +1 more source

Home - About - Disclaimer - Privacy